Redwood City, Calif.-based OncoMed Pharmaceuticals Inc. appointed John Lewicki as its CEO.
Lewicki, who will also join the company's board, will remain the company's president — a position he assumed in January.
Lewicki originally joined OncoMed in 2004 as senior vice president of research and development. He will lead the company as it advances its cancer treatments through clinical development.
He replaces Paul Hastings as CEO, who resigned at the beginning of 2018.